Latest Methylphenidate Stories
Study shows Clonicel(R) and stimulants combined provide greater improvement in symptoms than stimulants alone DURHAM, N.C., April 23 /PRNewswire/ -- Addrenex Pharmaceuticals, Inc. today announced positive results from a second phase 3 trial of Clonicel demonstrating that the combination of Clonicel with stimulant medications provided statistically significant improvements in attention deficit hyperactivity disorder (ADHD) symptoms compared to stimulant use alone. Clonicel is the company's...
TITUSVILLE, N.J., April 22 /PRNewswire/ -- Although Attention Deficit Hyperactivity Disorder (ADHD) is a condition commonly thought of as only affecting children, for nearly 9 million adults in the United States, ADHD is very much a reality. According to the National Institutes of Mental Health, adults with ADHD often struggle with getting organized, sticking to a job, remembering or keeping appointments and being productive. To view the Multimedia News Release, go to:...
TITUSVILLE, N.J., March 31 /PRNewswire/ -- The U.S. District Court for the District of Delaware has rendered a decision in the patent litigation between Alza Corporation, McNeil-PPC, Inc. and Andrx Pharmaceuticals LLC. McNeil Pediatrics, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., which markets CONCERTA(R) (methylphenidate HCI) Extended-Release Tablets CII, said the court held that the patent in suit is not valid or infringed by the filing of Andrx's Abbreviated New Drug...
PHILADELPHIA, March 20 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, announced today a voluntary market withdrawal/recall of thirty-nine (39) lots of the ADHD patch DAYTRANA (the lots of DAYTRANA patches affected by this action are listed below). Shire is taking this action because some DAYTRANA patches no longer meet their release liner removal specification, and as a result, patients and caregivers could have difficulties...
A small government study suggests that the narcolepsy drug modafinil "” a so-called "smart drug" increasingly being used to enhance cognitive abilities "” may be more addictive than doctors thought, the Associated Press reported. A study involving 10 healthy men found that the prescription drug Provigil (generic name: Modafinil) caused changes in the brain's pleasure center, very much like potentially habit-forming classic stimulants. College students often use Modafinil as an...
DUBLIN, March 16 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that it has decided to withdraw the European Marketing Authorization Application (MAA) for DAYTRANA(TM) (methylphenidate transdermal system) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). A request from European regulators to conduct an additional clinical study on DAYTRANA in a European patient population combined with the...
Cocaine use can have toxic effects on brain cells (neurons) that produce dopamine, say experts at Baylor College of Medicine in Houston in a report that appears today in the journal Psychiatry Research. Using brain tissue acquired after the subjects died, researchers microscopically compared the number of dopamine cells in the brains of 10 cocaine users to those in the brains of nine people matched for age who did not use the drug.They found significantly fewer dopamine cells, 16 percent,...
PHILADELPHIA and DUBLIN, February 20 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that it has signed an agreement with UCB to acquire the worldwide rights to EQUASYM(R) IR and XL (methylphenidate hydrochloride) (excluding the USA, Canada and Barbados) used for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). EQUASYM XL is approved and marketed in 10 countries (outside the USA, Canada, and...
Drugs prescribed for attention deficit hyperactivity disorder can induce hallucinations even when taken as directed, U.S. government researchers announced on Monday.U.S. Food and Drug Administration researchers reviewed the statistics from 49 clinical studies performed by manufacturers of the drugs and discovered psychosis and mania in some, counting those without risk factors. "Patients and physicians should be aware of the possibility that psychiatric symptoms consistent with psychosis...
A special issue of American Journal of Medical Genetics (AJMG): Part B: Neuropsychiatric Genetics presents a comprehensive overview of the latest progress in genetic research of Attention Deficit/Hyperactivity Disorder (ADHD). The issue covers major trends in the field of complex psychiatric genetics, underscoring how genetic studies of ADHD have evolved, and what approaches are needed to uncover its genetic origins.ADHD is a complex condition with environmental and genetic causes. It is...
